Navidea to Present Data from Lymphoseek Studies at RSNA, CTRC-AACR Meetings
Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) today announced that data from its Lymphoseek^® (technetium Tc 99m tilmanocept) studies in breast cancer and melanoma are being presented during the Radiological Society of North America Conference (RSNA) in Chicago and the CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.